Breaking News

NImmune Biopharma Launches with Phase 3-Ready Clinical Candidate Omilancor

The once-daily, oral, gut-restricted therapeutic for Ulcerative Colitis has potentially fast-to-market follow-on opportunities in Crohn’s disease and psoriasis.

NImmune Biopharma, a late-stage precision immunology biopharmaceutical company that develops biomarker-driven immunoregulatory therapeutics, announced its launch following the acquisition of omilancor, NIM-1324, and the entire LANCL portfolio of immunoregulatory therapeutic assets from Landos Biopharma, Inc. Omilancor is a Phase-3-ready, once-daily, oral, gut-restricted therapeutic for Ulcerative Colitis (UC) with potentially fast-to-market follow-on opportunities in Crohn’s disease (CD) and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters